Fondation Plan Alzheimer Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2014
NCT02164643
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Fondation Plan Alzheimer